Welcome to our dedicated page for Aptorum Group news (Ticker: APM), a resource for investors and traders seeking the latest updates and insights on Aptorum Group stock.
Aptorum Group Limited (NASDAQ: APM) is described in its public communications as a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapeutic assets for diseases with unmet medical needs, particularly in oncology, including orphan oncology indications, and infectious diseases. The company’s news flow also reflects its involvement in healthcare services and diagnostics collaborations, such as the co-development of the PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology.
Recent Aptorum news has highlighted a series of significant corporate and strategic developments. A central theme is the proposed all-stock merger with DiamiR Biosciences Corp., a molecular diagnostics company focused on minimally invasive tests for brain health and other diseases. Multiple joint press releases describe the Agreement and Plan of Merger, the expected ownership split between Aptorum shareholders and DiamiR stockholders, and the intention for DiamiR to become a wholly owned subsidiary of Aptorum, subject to shareholder approvals and customary closing conditions.
News items also cover DiamiR’s activities that are relevant to the combined story, including acceptance of scientific abstracts at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and regulatory milestones such as New York State approval for DiamiR’s APOE genotyping test. These updates emphasize DiamiR’s CLIA-certified, CAP-accredited laboratory, its microRNA-based platform for brain-enriched and inflammation-associated biomarkers, and its focus on brain health and neurodegenerative diseases.
In addition, Aptorum’s news releases describe financing transactions, including registered direct offerings of Class A ordinary shares and concurrent private placements of warrants, with stated uses of proceeds that include funding expenses related to the proposed merger and general working capital. Other announcements address Nasdaq listing matters, such as receipt of a minimum bid price deficiency notice and subsequent regaining of compliance with Nasdaq’s minimum bid price requirement.
Investors and observers following APM news can therefore expect updates on the progress of the proposed merger with DiamiR, scientific and regulatory developments connected to DiamiR’s diagnostics portfolio, Aptorum’s financing activities, and disclosures related to its Nasdaq listing status and SEC filings. The news stream collectively provides insight into how Aptorum presents its evolving strategy across oncology, infectious diseases, and, through the planned merger, brain health-focused diagnostics.
Aptorum Group (NASDAQ: APM) has received a notification from Nasdaq Stock Market on April 15, 2025, regarding non-compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2).
The company has been granted a 180-calendar-day grace period until October 14, 2025, to regain compliance with the listing requirements. During this period, the trading of APM shares on Nasdaq will continue unaffected.
To address this situation, Aptorum Group is evaluating various options, including the possibility of implementing a reverse stock split. The biotechnology company has expressed its commitment to maintaining its Nasdaq listing and will pursue necessary measures to achieve compliance within the specified timeframe.
Aptorum Group (NASDAQ: APM) has announced a $3.0 million registered direct offering of 1,535,000 Class A Ordinary Shares at $2.00 per share. The clinical stage biopharmaceutical company, focused on oncology, autoimmune and infectious diseases, expects to close the offering around January 3, 2025, subject to customary closing conditions.
Maxim Group serves as the sole placement agent. The offering is made pursuant to an effective shelf registration statement on Form F-3. The company will file a prospectus supplement with the SEC, and the gross proceeds are estimated at $3.0 million before deducting placement agent fees and other offering expenses.
Aptorum Group (NASDAQ: APM) reported financial results for H1 2024, with a net loss of $2.7 million, improved from $6.6 million in H1 2023. The company announced the termination of its reverse takeover transaction with Yoov Group due to market conditions affecting funding availability.
Key financial highlights include: Research and development expenses decreased to $2.0 million from $3.2 million; General and administrative fees reduced to $0.3 million from $1.3 million; and Legal and professional fees declined to $0.4 million from $1.7 million. As of June 30, 2024, cash and restricted cash totaled $0.8 million with total equity of $13.2 million.
Aptorum Group (Nasdaq: APM) reported a net loss of $4.3 million in 2023, down from $11.5 million in 2022. The company focused on lead projects, reducing net loss by $7.2 million. The proposed merger with YOOV Group Holding, if approved, will result in YOOV becoming a wholly-owned subsidiary of the combined company. Fiscal year end financial results showed a decrease in research and development, general and administrative, and legal expenses. Cash on hand was $2.0 million as of December 31, 2023. Aptorum Group is a clinical stage biopharmaceutical company focused on oncology, autoimmune diseases, and infectious diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.